CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Plasma from COVID-19 convalescent patientWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1078 Human immunoglobulin Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial

Background: On December 2019, a new human coronavirus infection (COVID-19) was detected in China. Its infectivity and virulence characteristics caused a rapid spread, being declared pandemic on March 2020. The mortality attributed to the infection ranges between 3 and 10%. Main risk factors are age, male sex, and chronic degenerative comorbidities. Due to the absence of therapeutic options, potential alternatives such as human immunoglobulin or plasma from convalescent patients have been administered. Due to the severity of the disease and the associated mortality, it is urgent to find therapeutic alternatives. Objective: To assess the safety and efficacy of the administration of Convalescent plasma vs human immunoglobulin in critically ill patients with COVID-19 infection. Material and methods: Randomized Controlled trial of patients diagnosed with respiratory infection by COVID-19, with severe respiratory failure without indication of mechanical ventilation, or those who due to their severity are intubated upon admission. Randomization will be performed 2:1 to receive plasma from convalescent patients or human immunoglobulin. Outcomes: The primary outcome will be time to discharge from hospital for improvement. The safety outcomes will be: Kirby index (PaO2/FiO2) evolution and dead.

NCT04381858 COVID-19 Pneumonia Drug: Plasma from COVID-19 convalescent patient Drug: Human immunoglobulin
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Mean days from admission as a suspected case of COVID with hospitalization criteria until discharge

Measure: Mean hospitalization time

Time: Through study completion, an average of 3 months

Description: Mean of delta of oxigenation index (PaO2/FiO2)

Measure: Mean Oxigenation index evolution

Time: Through study completion, an average of 3 months

Description: Rate of patients with evolution to severe ARDS (PaO2/FiO2 < 100)

Measure: Rate of severe ARDS

Time: Through study completion, an average of 3 months

Description: Rate of Dead caused by COVID-19 related complications and time to dead caused by COVID-19 complication

Measure: Rate and time to dead

Time: Through study completion, an average of 3 months

Description: Mean time with invasive mechanical ventilation

Measure: Mean time with invasive mechanical ventilation

Time: Through study completion, an average of 3 months

Secondary Outcomes

Description: Time to negativization of RT-qPCR SARS-CoV-2 test.

Measure: Time to Viral PCR Negativization

Time: Through study completion, an average of 3 months.


Related HPO nodes (Using clinical trials)